dupilumab
regeneron,sanofi
['sanofi', 'regeneron']
at #eadv2022, we re presenting late-breaking phase 3 data from a second clinical trial of our investigational medicine in adults with uncontrolled #prurigonodularis. read more: 
Official SanofiUS Twitter feed: news, updates & other info. For US residents only. https://t.co/pxa3CmSFxS